The Experts below are selected from a list of 14943 Experts worldwide ranked by ideXlab platform
Devon Greyson - One of the best experts on this subject based on the ideXlab platform.
-
balancing health and industrial policy objectives in the Pharmaceutical Sector lessons from australia
Health Policy, 2008Co-Authors: Steve Morgan, Meghan Mcmahon, Devon GreysonAbstract:Introduction: Policy-makers worldwide struggle to balance health with industrial policy objectives in the Pharmaceutical Sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal of “maintaining a responsible and viable medicines industry” into its National Medicines Policy. Methods: This case study was conducted via a narrative review that examined Australia’s experiences balancing health and industrial policy objectives in the Pharmaceutical Sector. The review included electronic databases, grey literature and government publications for reports on relevant Australian policy published over the period 1985–2007. Results: While Pharmaceutical companies claim that Australia’s pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Australia appears to have secured relatively low prices for generics and “me-too drugs” while paying internationally competitive prices for “breakthrough” medicines. Simultaneously, Australia has focused efforts on local Pharmaceutical investment through a variety of industry-targeted R&D incentive policies. Discussion: Despite the fact that policy reviews suggest that Australia has achieved balance between health and industrial policy objectives, the country continues to face criticism from industry that its health goals harm innovation and R&D. Recent reforms raise the question whether Australia can sustain the apparent balance. © 2008 Elsevier Ireland Ltd. All rights reserved.
-
Balancing health and industrial policy objectives in the Pharmaceutical Sector: Lessons from Australia
Health Policy, 2008Co-Authors: Steve Morgan, Meghan Mcmahon, Devon GreysonAbstract:Introduction Policy-makers worldwide struggle to balance health with industrial policy objectives in the Pharmaceutical Sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal of "maintaining a responsible and viable medicines industry" into its National Medicines Policy.Methods This case study was conducted via a narrative review that examined Australia's experiences balancing health and industrial policy objectives in the Pharmaceutical Sector. The review included electronic databases, grey literature and government publications for reports on relevant Australian policy published over the period 1985-2007.Results While Pharmaceutical companies claim that Australia's pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Australia appears to have secured relatively low prices for generics and "me-too drugs" while paying internationally competitive prices for "breakthrough" medicines. Simultaneously, Australia has focused efforts on local Pharmaceutical investment through a variety of industry-targeted R&D incentive policies.Discussion Despite the fact that policy reviews suggest that Australia has achieved balance between health and industrial policy objectives, the country continues to face criticism from industry that its health goals harm innovation and R&D. Recent reforms raise the question whether Australia can sustain the apparent balance.
Steve Morgan - One of the best experts on this subject based on the ideXlab platform.
-
balancing health and industrial policy objectives in the Pharmaceutical Sector lessons from australia
Health Policy, 2008Co-Authors: Steve Morgan, Meghan Mcmahon, Devon GreysonAbstract:Introduction: Policy-makers worldwide struggle to balance health with industrial policy objectives in the Pharmaceutical Sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal of “maintaining a responsible and viable medicines industry” into its National Medicines Policy. Methods: This case study was conducted via a narrative review that examined Australia’s experiences balancing health and industrial policy objectives in the Pharmaceutical Sector. The review included electronic databases, grey literature and government publications for reports on relevant Australian policy published over the period 1985–2007. Results: While Pharmaceutical companies claim that Australia’s pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Australia appears to have secured relatively low prices for generics and “me-too drugs” while paying internationally competitive prices for “breakthrough” medicines. Simultaneously, Australia has focused efforts on local Pharmaceutical investment through a variety of industry-targeted R&D incentive policies. Discussion: Despite the fact that policy reviews suggest that Australia has achieved balance between health and industrial policy objectives, the country continues to face criticism from industry that its health goals harm innovation and R&D. Recent reforms raise the question whether Australia can sustain the apparent balance. © 2008 Elsevier Ireland Ltd. All rights reserved.
-
Balancing health and industrial policy objectives in the Pharmaceutical Sector: Lessons from Australia
Health Policy, 2008Co-Authors: Steve Morgan, Meghan Mcmahon, Devon GreysonAbstract:Introduction Policy-makers worldwide struggle to balance health with industrial policy objectives in the Pharmaceutical Sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal of "maintaining a responsible and viable medicines industry" into its National Medicines Policy.Methods This case study was conducted via a narrative review that examined Australia's experiences balancing health and industrial policy objectives in the Pharmaceutical Sector. The review included electronic databases, grey literature and government publications for reports on relevant Australian policy published over the period 1985-2007.Results While Pharmaceutical companies claim that Australia's pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Australia appears to have secured relatively low prices for generics and "me-too drugs" while paying internationally competitive prices for "breakthrough" medicines. Simultaneously, Australia has focused efforts on local Pharmaceutical investment through a variety of industry-targeted R&D incentive policies.Discussion Despite the fact that policy reviews suggest that Australia has achieved balance between health and industrial policy objectives, the country continues to face criticism from industry that its health goals harm innovation and R&D. Recent reforms raise the question whether Australia can sustain the apparent balance.
Amir Ali Ebadi Fard Azar - One of the best experts on this subject based on the ideXlab platform.
-
Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study
Risk management and healthcare policy, 2019Co-Authors: Farbod Ebadi Fardazar, Ali Sarabi Asiabar, Hossein Safari, Mojgan Asgari, Ali Saber, Amir Ali Ebadi Fard AzarAbstract:Introduction Improving public health through providing affordable and accessible Pharmaceuticals is among the concerns of governments worldwide. This study aimed to analyze Iran's Pharmaceutical Sector policies in order to identify the challenges and suggest some strategic solutions to overcome such challenges. Methods Top managers (15), middle managers (10), and operational managers (5) working in the Food and Drug Administration of Iranian Ministry of Health along with community pharmacists (5) participated in a qualitative study using semi-structured in-depth interviews. Data were recorded, transcribed, and then analyzed via MAXQDA 10 software. Results Policies for national Pharmaceutical Sector were divided into four groups of "research & development", "import & export", "Pharmaceutical procurement", and "Pharmaceutical supply and distribution". Then, the challenges faced by each Sector were extracted. Considering the challenges, some policy options were recommended for growth and development of national Pharmaceutical Sector. Conclusion Iran's Pharmaceutical Sector has managerial and administrative differences compared with overseas Pharmaceutical Sectors. These differences are the main reasons for the current status of Iran's Pharmaceutical Sector and have put Iran behind foreign Pharmaceutical Sectors. Iran's Pharmaceutical Sector has endured many critical periods during recent decades and has gained great experience during these stages. Therefore, it is believed that Iran's Pharmaceutical Sector, with its experience and potential, is capable of producing world-level medicines.
Toine Pieters - One of the best experts on this subject based on the ideXlab platform.
-
Restoring trust in the Pharmaceutical Sector on the basis of the SSRI case.
Drug discovery today, 2013Co-Authors: Juan Francisco Hernandez, Ghislaine J.m.w. Van Thiel, Aukje K. Mantel-teeuwisse, Jan A.m. Raaijmakers, Toine PietersAbstract:The lack of public trust in the Pharmaceutical Sector (i.e. industry, authorities and doctors) could compromise the future of drug development and the regulatory system. Public trust integrates two important components, namely the vulnerability of the truster and the competence of the trustee. Because trust appears to have eroded as a result of drug safety controversies, this paper analyzes the role of public trust during the selective serotonin reuptake inhibitor (SSRI) and suicidality controversy focusing on the aforementioned trust components. Because the competence component of trust is argued to be paramount in determining and maintaining public trust, the SSRI case shows that this component is a part of public trust where these institutions can build on, and might therefore be better used to substantiate and reinforce, public trust. Efforts to build trust should rely on the ethical, professional (competence) and societal commitment of institutions and individuals to protect the vulnerability of the public during controversies. Because shared values can create trust or increase its levels within a specific environment, industry, authorities and physicians ought to develop novel and cooperative strategies to highlight their shared values and motivations. Rules, regulations and settlements are indispensable tools but undue regulation is costly and can backfire on the rather sensitive trust relationships in the Pharmaceutical Sector.
Meghan Mcmahon - One of the best experts on this subject based on the ideXlab platform.
-
balancing health and industrial policy objectives in the Pharmaceutical Sector lessons from australia
Health Policy, 2008Co-Authors: Steve Morgan, Meghan Mcmahon, Devon GreysonAbstract:Introduction: Policy-makers worldwide struggle to balance health with industrial policy objectives in the Pharmaceutical Sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal of “maintaining a responsible and viable medicines industry” into its National Medicines Policy. Methods: This case study was conducted via a narrative review that examined Australia’s experiences balancing health and industrial policy objectives in the Pharmaceutical Sector. The review included electronic databases, grey literature and government publications for reports on relevant Australian policy published over the period 1985–2007. Results: While Pharmaceutical companies claim that Australia’s pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Australia appears to have secured relatively low prices for generics and “me-too drugs” while paying internationally competitive prices for “breakthrough” medicines. Simultaneously, Australia has focused efforts on local Pharmaceutical investment through a variety of industry-targeted R&D incentive policies. Discussion: Despite the fact that policy reviews suggest that Australia has achieved balance between health and industrial policy objectives, the country continues to face criticism from industry that its health goals harm innovation and R&D. Recent reforms raise the question whether Australia can sustain the apparent balance. © 2008 Elsevier Ireland Ltd. All rights reserved.
-
Balancing health and industrial policy objectives in the Pharmaceutical Sector: Lessons from Australia
Health Policy, 2008Co-Authors: Steve Morgan, Meghan Mcmahon, Devon GreysonAbstract:Introduction Policy-makers worldwide struggle to balance health with industrial policy objectives in the Pharmaceutical Sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal of "maintaining a responsible and viable medicines industry" into its National Medicines Policy.Methods This case study was conducted via a narrative review that examined Australia's experiences balancing health and industrial policy objectives in the Pharmaceutical Sector. The review included electronic databases, grey literature and government publications for reports on relevant Australian policy published over the period 1985-2007.Results While Pharmaceutical companies claim that Australia's pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Australia appears to have secured relatively low prices for generics and "me-too drugs" while paying internationally competitive prices for "breakthrough" medicines. Simultaneously, Australia has focused efforts on local Pharmaceutical investment through a variety of industry-targeted R&D incentive policies.Discussion Despite the fact that policy reviews suggest that Australia has achieved balance between health and industrial policy objectives, the country continues to face criticism from industry that its health goals harm innovation and R&D. Recent reforms raise the question whether Australia can sustain the apparent balance.
